170 results
Page 6 of 9
424B5
k533zq 99n
22 Oct 20
Prospectus supplement for primary offering
8:45am
6-K
EX-99.1
4cv115okstwijacg1p
13 Oct 20
Report of Foreign Private Issuer
9:30am
6-K/A
EX-99.2
w0f2rjm1am3dda5
13 Oct 20
Condensed Consolidated Financial Statements
9:16am
6-K
EX-99.1
bixpi455rd 71e
1 Oct 20
Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition
6:06am
6-K
EX-99.1
6czy jwlv
16 Sep 20
Enlivex Announces Allowance of New Chinese Patent Covering Allocetra Immunotherapy
8:02am
6-K
EX-99.1
8ot2py0g6 17
25 Aug 20
Enlivex Announces Allowance of New U.S. Patent Covering Allocetra Immunotherapy
8:02am
6-K
EX-99.2
1xqdsq 0lkf
14 Aug 20
Condensed Consolidated Financial Statements
4:23pm
6-K
EX-99.1
f1u7clh
10 Aug 20
Enlivex Announces Dosing of First Patient in Clinical Trial of Allocetra in COVID-19 Patients with Severe Illness Respiratory Failure
8:02am
6-K
EX-99.1
tcrj7of50fk8r
18 Jun 20
Enlivex Announces Allowance of New Japanese Patent Application Covering ALLOCETRA Immunotherapy
8:32am
6-K
EX-99.1
xyz8gpyg5 fo
28 May 20
Report of Foreign Private Issuer
9:25am
6-K
EX-99.1
5nj848i apja2glkc0i
19 May 20
Annual and Extraordinary General Meeting of Shareholders
8:04am
6-K
EX-99.2
x48a9
18 May 20
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
n6b xqqc0w6ccbvf2
7 May 20
Enlivex Announces Initiation of Multi-Center Phase II Investigator-Initiated Clinical Trial of Allocetra in COVID-19 Patients
8:01am
6-K
EX-99.1
3vbi3vq nxfp4p
13 Apr 20
Enlivex Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical Trials
8:32am
6-K
EX-99.1
hfp3aw5b7r 7v065u6h9
18 Mar 20
Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis
8:26am
6-K
EX-1.1
q5bpjoy
5 Mar 20
Report of Foreign Private Issuer
8:16am
6-K
EX-99.2
tp28l 3krmfaq2d
5 Mar 20
Report of Foreign Private Issuer
8:16am
6-K
EX-99.1
j0433vjx7hbinqitpqgk
5 Mar 20
Report of Foreign Private Issuer
8:16am
424B5
wso0z65r
3 Mar 20
Prospectus supplement for primary offering
5:13pm